FORMULATION OF NANOSTRUCTURED LIPID CARRIERS OF HALOPERIDOL PREPARED BY USING CLARIFIED BUTTER
DOI:
https://doi.org/10.22159/ijap.2023v15i2.46759Keywords:
Haloperidol, Haloperidol clarified butter, Nano-structured lipid carriers, Factorial designAbstract
Objective: To develop the nanostructured lipid carriers (NLC’s) using clarified butter.
Methods: Haloperidol-loaded microemulsion templates were prepared by using Smix of Tween 80 and propylene glycol in the ratio 1:2. The selection of the mixture of surfactant and co-surfactant (Smix) and their appropriate proportion were decided by the traditional way of construction of pseudo ternary phase diagrams. 22 factorial design was used to check the amenability of the formulation for its successful scale-up. Sonication time and the amount of Smix were selected as independent variables and their influence on the globular size (Y1) of the microemulsions formed was evaluated by using statistical models. Composition of the optimized microemulsion template was further used to prepare haloperidol-loaded NLC’s by ‘microemulsion quenching method’.
Results: The microemulsion formulations containing Tween 80 as a surfactant and propylene glycol as a co-surfactant exhibited the smallest globular size and hence this composition was used further to implement factorial design as design of experiments. The statistical analysis of the data suggested that the microemulsion formulation can be scaled up successfully. NLC’s were prepared from the optimized microemulsion formulation as template. The globular size of NLC’s was confirmed by Transmission Electron Microscopy and was observed to be in the range of 300 to 600 nm.
Conclusion: The present work suggested that the latency of the clarified butter as a natural blend of solid lipid and liquid lipids can be successfully explored to prepare nanostructured lipid carriers.
Downloads
References
Erdo F, Bors LA, Farkas D, Bajza A, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155-70. doi: 10.1016/j.brainresbull.2018.10.009. PMID 30449731.
Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: A novel mechanistic hypothesis. CNS Drugs. 2013 Mar;27(4):249-57. doi: 10.1007/s40263-013-0054-1, PMID 23533011.
Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol. 2019 Feb 5;844:231-40. doi: 10.1016/j.ejphar.2018.12.003. PMID 30529195.
Martins PP, Smyth HDC, Cui Z. Strategies to facilitate or block nose-to-brain drug delivery. Int J Pharm. 2019;570:118635. doi: 10.1016/j.ijpharm.2019.118635. PMID 31445062.
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol. 2019 Jun;51:255-67. doi: 10.1016/j.jddst.2019.02.017.
Shevalkar G, Vavia P. Solidified nanostructured lipid carrier (S-NLC) for enhancing the oral bioavailability of ezetimibe. J Drug Deliv Sci Technol. 2019 Oct;53:111211. doi: 10.1016/j.jddst.2019.101211.
Ligia NMR, Marcia CB, Viviane AG, Gustavo HR da Silva, Veronica MC, Simone RC, Barbara OP, Daisy M, Eneida P. Natural lipids-based NLC containing lidocaine: From pre-formulation to in vivo studies. Eur J Pharm Sci. 2017 Aug 30;106:102-12. doi: 10.1016/j.ejps.2017.05.060.
Khunt D, Shah B, Misra M. Role of butter oil in brain targeted delivery of quetiapine fumarate microemulsion via the intranasal route. J Drug Deliv Sci Technol. 2017 May;40:11-20. doi: 10.1016/j.jddst.2017.05.004.
Mortensen BK. Anhydrous milk fat/butter oil and ghee. Enc Dai Sci. 2016. p. 515-21. doi: 10.1016/B978-0-08-100596-5.00647-8.
Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules. Innovative Food Science & Emerging Technologies. 2013;19:29-43. doi: 10.1016/j.ifset.2013.03.002.
Slavomira D, Ranjita S, Eliana BS. Nanostructures for novel therapy. 1st ed. Philadelphia; 2017. p. 811.
Salama HA, Mahmoud AA, Kamel AO, Abdel Hady M, Awad GAS. Phospholipid-based colloidal poloxamer–nanocubic vesicles for brain targeting via the nasal route. Colloids and Surfaces B: Biointerfaces. 2012;100:146-54. doi: 10.1016/j.colsurfb.2012.05.010.
Bhavbhuti MM. Gourmet and health-promoting specialty oils. 1st ed. AOCS Press; 2009. p. 527. doi: 10.1016/C2015-0-02415-7.
Antony J. Design of experiments for engineers and scientists. 2nd ed. Elsevier; 2014. p. 63. doi: 10.1016/B978-0-7506-4709-0.
Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)–based gel of valdecoxib. Drug Dev Ind Pharm. 2006 Sep;32(8):911-18. doi: 10.1080/03639040600814676, PMID 16954103.
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000 Dec 6;45(1):89-121. doi: 10.1016/S0169-409X(00)00103-4.
Khatri P, Shao J. Mechanism and structural factors of lipid and surfactant in the formation of self-emulsified nanoemulsion. J Pharm Sci. 2018 Aug;107(8):2198-207. doi: 10.1016/j.xphs.2018.03.024, PMID 29626536.
Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47(1):65-81. doi: 10.1016/s0169-409x(00)00122-8. PMID 11251246.
Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014 May;71:2-14. doi: 10.1016/j.addr.2013.08.008. PMID 23981489.
Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008 Jan;346(1-2):124-32. doi: 10.1016/j.ijpharm.2007.05.060, PMID 17651933.
Karuppusami G, Gandhinathan R. Pareto analysis of critical success factors of total quality management: A literature review and analysis. TQM Mag. 2006 Jul;18(4):372-85. doi: 10.1108/09544780610671048.
Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018 May 18;10(2):57. doi: 10.3390/pharmaceutics10020057, PMID 29783687.
El-Assal MI, Samuel D. Optimization of rivastigmine chitosan nanoparticles for neurodegenerative alzheimer; in vitro and ex vivo characterizations. Int J Pharm Pharm Sci. 2021;14(1):17-27. doi: 10.22159/ijpps.2022v14i1.43145.
Kumar B, Garg V, Singh A, Pandey NK, Singh S, Panchal S. Investigation and optimization of formulation parameters for the self-nano emulsifying delivery system of two lipophilic and gastrointestinal labile drugs using box-Behnken design. Asian J Pharm Clin Res. 2018;11(2):12-8. doi: 10.22159/ajpcr.2018.v11s2.28585.
Mojahedian MM, Daneshamouz S, Samani SM, Zargaran A. A novel method to produce solid lipid nanoparticles using n-butanol as an additional co-surfactant according to the o/w microemulsion quenching technique. Chem Phys Lipids. 2013 Sep;174:32-8. doi: 10.1016/j.chemphyslip.2013.05.001. PMID 23743405.
Caboi F, Lazzari P, Pani L, Monduzzi M. Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. Chem Phys Lipids. 2005 Jun;135(2):147-56. doi: 10.1016/j.chemphyslip.2005.02.010, PMID 15921975.
Mohammed E, Mohammad M. Nanostructured lipid carriers (NLCs) as drug delivery (NLCs) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm J. 2021 Sep:29(9);999-1012. doi: 10.1016/j.jsps.2021.07.015.
Published
How to Cite
Issue
Section
Copyright (c) 2023 SHARWAREE RAJAN HARDIKAR, DANIYAL MOHD AKBAR ANSARI, NILESH ANIL PATIL
This work is licensed under a Creative Commons Attribution 4.0 International License.
